GLUT expression and 18F-FDG uptake in breast cancer cell lines
© Abrantes et al; licensee BioMed Central Ltd. 2010
Published: 24 September 2010
Positron emission tomography (PET) using the radiolabeled glucose analogue 18F-FDG allows uncovering glycolysis processes within cancer cells and reveals high value in diagnosis, staging, relapse and therapeutic response evaluation in several malignancies. Breast cancer presents considerable variability when it comes to 18F-FDG uptake, which results in different sensitivity and specificity values related to this technique. 18F-FDG enters the cells through glucose transporters (GLUTs). Therefore, this study aims to determine the pattern of 18F-FDG uptake in various breast cancer cell lines with different hormonal and HER2 receptor’s expressions, and to set a correlation with the expression of GLUT’s 1 and 3.
The studies were performed in three different human breast cancer cell lines, MCF-7, HCC1806 and HCC1954. MCF-7 express estrogen and progesterone receptors (ER and PR), HCC1806 cells are triple negative and HCC1954 are negative for hormonal receptors, but overexpress HER2/neu. GLUT-1 and GLUT-3 expressions were assessed by flow cytometry.
Our results show that, besides HCC1806 and HCC1954 cells present higher GLUT-1 and GLUT-3 levels than MCF-7, we observe a higher 18F-FDG uptake in HCC1954 cells. In fact, HCC1806 cells show the lower 18F-FDG uptake comparing with other cell lines.
These results suggest that despite the dependability of GLUT-1 and GLUT-3 isoforms’ overexpression for 18F-FDG uptake, these receptors do not seem to be the unique responsible. Considering the absence of correlation between GLUT’s expression and 18F-FDG uptake, ER, PR and principally HER2/neu gains an apparent relevance in this process.
This article is published under license to BioMed Central Ltd.